A recent phase III Keynote-811 study indicated that trastuzumab combined with pembrolizumab and chemotherapy markedly revolutionized the treatment of unresectable or metastatic HER2-positive GC or gastroesophageal junction adenocarcinoma [5]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.